Acutus Medical, Inc. (AFIB)
| Market Cap | 710.77M |
| Revenue (ttm) | 6.56M |
| Net Income (ttm) | n/a |
| Shares Out | 16.08M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $26.00 |
| Previous Close | $25.69 |
| Change ($) | 0.31 |
| Change (%) | 1.21% |
| Day's Open | 25.63 |
| Day's Range | 25.02 - 26.26 |
| Day's Volume | 220,508 |
| 52-Week Range | 22.87 - 37.65 |
News
CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagno...
CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagno...
About AFIB
Acutus Medical, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. It offers AcQMap console and workstation, an advanced imaging, navigation, and mapping system for physicians to map, treat, re-map, and adjust additional therapy as needed; and Patient Electrode Kit that is required in every procedure to provide cardiac signals, catheter localization, and AcQMap system grounding. The company also provid... [Read more...]
| Industry Medical Devices | IPO Date Aug 6, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol AFIB |
Financial Performance
In 2019, Acutus Medical's revenue was $2.84 million, an increase of 30.93% compared to the previous year's $2.17 million. Losses were -$97.04 million, 102.6% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Acutus Medical stock is "Buy." The 12-month stock price forecast is 34.75, which is an increase of 33.65% from the latest price.